Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with glioblastoma or grade 4 astrocytoma, confirmed by a tissue test (biopsy or surgery)
- People aged 18 or older
- People who are well enough to carry out some daily activities (measured by a standard health scale called the Karnofsky Performance Scale, with a score of at least 60)
- People whose blood counts and organ function (including white blood cells, platelets, liver, and kidneys) fall within acceptable ranges as measured by blood tests
- People who are able to use reliable contraception during the study, as radiation therapy may be harmful to an unborn child — this applies to both male and female participants who are capable of having children
- People who are able to understand the study and are willing to sign a consent form agreeing to take part
Who may not be able to join:
- People who are unable to have MRI scans
- People who are currently taking part in another experimental cancer treatment trial at the time of joining
- People who have previously had a course of radiation therapy to the brain that overlaps with the area that would be treated in this trial
- People with serious uncontrolled health conditions, such as an active infection, heart failure, unstable chest pain, irregular heart rhythm, or mental health or personal circumstances that would make it difficult to follow the study requirements
- People who are pregnant or breastfeeding
- Female participants of childbearing potential who are unable or unwilling to use an accepted form of contraception throughout the entire study period and for up to 12 weeks after the study ends
- Male participants who are unwilling to use effective contraception for the same period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kristin Redmond, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phone: 410-614-1642
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in APTw signal (Efficacy of APT-RT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.